|Bid||40.610 x 1500|
|Ask||40.620 x 1200|
|Day's Range||40.290 - 40.660|
|52 Week Range||37.200 - 45.580|
|PE Ratio (TTM)||45.76|
|Dividend & Yield||1.95 (4.65%)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis GlaxoSmithKline Plc reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of GlaxoSmithKline Plc – Novartis AG Sponsored ADR and Innoviva, Inc. (NVS-US and INVA-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 9,476.11 million, Net ... Read more (Read more...)
We don't think the current price accounts for the company's pipeline.
Britain's two big drugmakers face very different challenges but they share a common problem: how to convince investors that their dividends are safe. With both stocks offering a dividend yield of more than 5 percent, AstraZeneca and GlaxoSmithKline provide islands of decent income in a sea of low returns. The chief executives of both companies faced a barrage of questions from analysts about future payouts and were forced to defend their dividend strategies at post-results meetings this week.